Dr. Mark Groh, M.D.
Claim this profileMission Health & Hospitals
Affiliated Hospitals
Mission Health & Hospitals
Mission Hospital
Clinical Trials Mark Groh, M.D. is currently running
Accuryn Monitoring System
for Cardiac Surgery
The Accuryn Registry Study is an open-ended, global, multi-center, retrospective and prospective, single-arm data collection study with an FDA cleared device. The target population are cardiovascular surgery patients. Physiologic data measurements will be collected from enrolled subjects using electronic medical records and data streams via the Accuryn Monitoring System.
Recruiting
1 award
N/A
4 criteria
Tendyne Transcatheter Mitral Valve System
for Mitral Regurgitation
Prospective, controlled, multicenter clinical investigation with four trial cohorts: Randomized, Non-repairable, Severe Mitral Annular Calcification (MAC) and Severe Mitral Annular Calcification Continued Access Protocol (MAC CAP). Subjects in the Randomized cohort will be randomized in a 1:1 ratio to the trial device or to the MitraClip system. Subjects in the Non-repairable, Severe MAC, and Severe MAC CAP cohorts will receive the trial device. The objective of the Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation (SUMMIT) is to evaluate the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System for the treatment of patients with symptomatic, moderate-to-severe or severe mitral regurgitation or for patients with symptomatic mitral valve disease due to severe mitral annular calcification. This randomized controlled trial will provide the opportunity to evaluate the safety and clinical benefits of the Tendyne Transcatheter Mitral Valve System compared to the MitraClip System in patients with symptomatic, moderate-to-severe or severe mitral regurgitation, within approved MitraClip indications. In addition, the safety and effectiveness of the Tendyne Transcatheter Mitral Valve System will be evaluated in patients with severe mitral annular calcification who are at prohibitive risk for mitral valve surgery. Patients who are not suitable for mitral valve surgery for reasons other than severe mitral annular calcification and are also not suitable for transcatheter repair with MitraClip, will be enrolled in the Non-repairable cohort. Subjects will be seen at screening, pre- and post-procedure, discharge, 30 days, 3 months, 6 months, and annually through 5 years.
Recruiting
1 award
N/A
4 criteria
More about Mark Groh, M.D.
Clinical Trial Related
6 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 2 Active Clinical Trials
Treatments Mark Groh, M.D. has experience with
- Portico™ NG Valve And FlexNav™ Delivery System
- Portico™ NG (Navitor) Valve And FlexNav™ Delivery System
- Navitor Titan Valve (35mm) Valve And Large FlexNav™ Delivery System
- Evolut FX TAVR System
- Medtronic Evolut PRO+ TAVR System
- Navitor Transcatheter Aortic Valve Implantation (TAVI) System
Breakdown of trials Mark Groh, M.D. has run
Von Willebrand Disease
Aortic Valve Stenosis
Valvular Heart Disease
Aortic Stenosis
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Mark Groh, M.D. specialize in?
Mark Groh, M.D. focuses on Von Willebrand Disease and Aortic Valve Stenosis. In particular, much of their work with Von Willebrand Disease has involved treating patients, or patients who are undergoing treatment.
Is Mark Groh, M.D. currently recruiting for clinical trials?
Yes, Mark Groh, M.D. is currently recruiting for 2 clinical trials in Asheville North Carolina. If you're interested in participating, you should apply.
Are there any treatments that Mark Groh, M.D. has studied deeply?
Yes, Mark Groh, M.D. has studied treatments such as Portico™ NG Valve and FlexNav™ Delivery System, Portico™ NG (Navitor) Valve and FlexNav™ Delivery System, Navitor Titan Valve (35mm) Valve and Large FlexNav™ Delivery System.
What is the best way to schedule an appointment with Mark Groh, M.D.?
Apply for one of the trials that Mark Groh, M.D. is conducting.
What is the office address of Mark Groh, M.D.?
The office of Mark Groh, M.D. is located at: Mission Health & Hospitals, Asheville, North Carolina 28801 United States. This is the address for their practice at the Mission Health & Hospitals.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.